BryanPSchneiderMD

PubMed

• Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs.
  Hyunwoo Koo, Tayler B Smith, John T Callaghan, Wilberforce Osei, Steven M Bray
  Clinical Pharmacology and Therapeutics. 2025-04-01
• Elevated tumor mutation burden in patients with cancer with underlying HIV infection: data from the Oncology Research Information Exchange Network (ORIEN).
  Anna E Coghill, Nathan Van Bibber, Robert A Baiocchi, Susanne M Arnold, Gregory Riedlinger
  Cancer Epidemiology, Biomarkers & Prevention. 2025-02-28
• Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer.
  Catherine E Mosher, Shieun Lee, Elizabeth L Addington, Seho Park, Ashley B Lewson
  Journal of Clinical Oncology. 2025-02-20

Journal Articles

• Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer  
  Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
• Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)  
  Hope S Rugo, Bryan P Schneider, Alan Venook, Clinical Cancer Research
• Survival in Metastatic Recurrent Breast Cancer: No Evidence for Improvement Due to Metastastic Therapies Over the Past Three Decades  
  Tevaarwerk A, Gray R, Schneider BP, Smith ML, Wagner L, Fetting J, Davidson N, Tevaarwerk A, Gray R, Schneider BP, Smith ML, Wagner L, Fetting J, Davidson N,, Cancer, 3/15/2013
• Prognostic and predictive value of tumor VEGF gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 21...  
  Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh, Perez EA, Shenkier TN, , Sledge GW, Sparano JA, Davidson..., Clinical Cancer Research, 1/22/2013
• Functional microRNAs in Alzheimer’s disease and cancer: Differential regulation of common mechanisms and pathways  
  Holohan KN, Lahiri DK, Schneider BP, Foroud T, Saykin AJ, Frontiers in Non-Coding RNA, 1/1/2013
• Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment  
  Schneider BP, Shen F, Miller KD, Lancet Oncology, 10/1/2012
• A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors  
  Jhaveri K, Miller KD, Rosen L, Schneider BP, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S, Clinical Cancer Research, 1/1/2012
• Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer  
  Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner, TA, Wolff AC, Sledge GW, Wood W, Davidson NE, and Sparano JA, Journal of Clinical Oncology, 1/1/2011
• Cancer associated alteration of pericentromeric heterochromatin may contribute to chromosome instability  
  Slee R, Steiner CM, Herbert B-S, Vance GH, Hickey RJ, Schwarz T, Christan S, Radovich M, Schneider BP, Schindelhauer D and Grimes BR, Oncogene, 1/1/2011
• Anti–Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?  
  Schneider B and Sledge G, Journal of Clinical Oncology, 1/1/2011
• Compliance differences between patients with breast cancer in university and county hospitals  
  Komenaka I, Pennington R, Schneider B,. Hsu C, Norton L, Clare S, Zork N, Goulet R, Clinical Breast Cancer, 10/1/2010
• Evaluating the role of serotonin on neuropsychological function after breast cancer using acute tryptophan depletion  
  Von Ah D, Skaar R, Unverzagt F, Yu M, Wu J, Schneider B, Storniolo A, Moser L, Ryker K, Milata J, & Carpenter J, Biological Research for Nurses, 4/1/2010
• Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group  
  Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N, Journal of Thoracic Oncology 5, 1/1/2010
• Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy  
  Otte J, Flockhart D, Hayes D, Storniolo A, Stearns V, Schneider B, Henry N, Azzouz F, Nguyen A, Lemler S, Hayden J, Jeter S, Wright L, Carpenter JS, Menopause, 1/1/2009
• Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion  
  Carpenter J, Yu M, Wu J, Von Ah D, Milata J, Otte J, Johns S, Schneider B, Storniolo A, Salomon R, Desta Z, Cao D, Jin Y, Philips S, Skaar T, Menopause, 1/1/2009
• A phase I dose escalation and pharmacokinetic study of Vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors  
  Chiorean E, Malireddy S, Younger A, Jones D, Waddell M, Sloop M, Yu M, Hall S, Schneider B, & Sweeney C, Cancer Chemotherapy and Pharmacology, 1/1/2009
• Intrinsic subtype-associated changes in the plasma proteome in breast cancer  
  Nakshatri H, Qi G, You J, Kerry B, Schneider B, Zon R, Buck C, Regnier F, Wang M, Proteomics Clinical Applications, 1/1/2009
• Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?  
  Schneider B, Sledge G, Breast Cancer Research, 1/1/2009
• The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer  
  Schneider B, Radovich M, & Miller K, Clinical Cancer Res, 1/1/2009
• Triple negative breast cancer: risk factors to potential targets  
  Schneider B, Winer E, Foulkes W, Garber J, Perou C, Richardson A, Sledge G, Carey L, Clinical Cancer Research, 1/1/2008
• Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compare...  
  Schneider B, Wang M, Radovich M, Sledge G, Badve S, Thor A, Flockhart D, Hancock B, Davidson N, and Miller K, Journal of Clinical Oncology, 1/1/2008
• A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors  
  Kesler K, Rieger K, Hammoud Z, Kruter L, Perkins S, Turrentine M, Schneider B, Einhorn L, Brown J, Annals of Thoracic Surgery, 1/1/2008
• Drug Insight: VEGF as a therapeutic target for breast cancer  
  Schneider B and Sledge G, Nature Clinical Practice Oncology, 1/1/2007
• Is the blood-brain barrier relevant in metastatic germ cell tumor?  
  Azar J, Schneider B, Einhorn L, International Journal of Radiation Oncology, Biology, Physics, 1/1/2007
• A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alfa2b in patients with solid tumors  
  Schneider B, Fukunaga A, Murry D, Yoder C, Fife K, Foster A, Rosenberg L, Kelich S, Li L, and Sweeney C, Cancer Chemotherapy and Pharmacology, 1/1/2007
• Join now to see all

Lectures

• How to Recognize Germline Mutations Found During Somatic Tumor Testing 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018